Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology
International audience Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progr...
Published in: | European Journal of Heart Failure |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Other Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
HAL CCSD
2019
|
Subjects: | |
Online Access: | https://hal.univ-lorraine.fr/hal-03764243 https://hal.univ-lorraine.fr/hal-03764243/document https://hal.univ-lorraine.fr/hal-03764243/file/European%20J%20of%20Heart%20Fail%20-%202019%20-%20de%20Boer%20-%20Towards%20better%20definition%20%20quantification%20and%20treatment%20of%20fibrosis%20in%20heart.pdf https://doi.org/10.1002/ejhf.1406 |
id |
ftccsdartic:oai:HAL:hal-03764243v1 |
---|---|
record_format |
openpolar |
institution |
Open Polar |
collection |
Archive ouverte HAL (Hyper Article en Ligne, CCSD - Centre pour la Communication Scientifique Directe) |
op_collection_id |
ftccsdartic |
language |
English |
topic |
Fibrosis Heart failure Biomarkers Fibroblast Matrix Prognosis Imaging [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system |
spellingShingle |
Fibrosis Heart failure Biomarkers Fibroblast Matrix Prognosis Imaging [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system de Boer, Rudolf, A de Keulenaer, Gilles Bauersachs, Johann Brutsaert, Dirk Cleland, John, G Diez, Javier Du, Xiao‐jun Ford, Paul Heinzel, Frank, R Lipson, Kenneth, E Mcdonagh, Theresa Lopez-Andres, Natalia Lunde, Ida, G Lyon, Alexander, R Pollesello, Piero Prasad, Sanjay, K Tocchetti, Carlo, G Mayr, Manuel Sluijter, Joost P.G. Thum, Thomas Tschöpe, Carsten Zannad, Faiez Zimmermann, Wolfram‐hubertus Ruschitzka, Frank Filippatos, Gerasimos Lindsey, Merry, L Maack, Christoph Heymans, Stephane Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology |
topic_facet |
Fibrosis Heart failure Biomarkers Fibroblast Matrix Prognosis Imaging [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system |
description |
International audience Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins - resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research. |
author2 |
University Medical Center Groningen Groningen (UMCG) University of Antwerp (UA) Medizinische Hochschule Hannover = Hannover Medical School (MHH) University of Glasgow Center for Applied Medical Research Plamplona (CIMA) Universidad de Navarra Pamplona (UNAV) Clínica Universidad de Navarra Pamplona Baker Heart and Diabetes Institute (AUSTRALIA) Galecto Biotech Charité Campus Virchow-Klinikum (CVK) Charité - UniversitätsMedizin = Charité - University Hospital Berlin FibroGen Inc. King's College Hospital (KCH) Universidad Pública de Navarra Espagne = Public University of Navarra (UPNA) Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA) Universidad Pública de Navarra Espagne = Public University of Navarra (UPNA)-Universidad de Navarra Pamplona (UNAV)-Clínica Universidad de Navarra Pamplona University of Oslo (UiO) Oslo University Hospital Oslo Royal Brompton Hospital Orion Pharma University of Naples Federico II = Università degli studi di Napoli Federico II King‘s College London University Medical Center Utrecht Institute of Molecular and Translational Therapeutic Strategies (IMTTS) German Center for Cardiovascular Research (DZHK) Berlin Institute of Health (BIH) Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P) Centre d'investigation clinique Nancy (CIC) Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL) Défaillance Cardiovasculaire Aiguë et Chronique (DCAC) Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL) Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT) Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT ) University Medical Center Göttingen (UMG) University hospital of Zurich Zurich “Attikon” University Hospital University of Mississippi Medical Center (UMMC) Julius-Maximilians-Universität Würzburg (JMU) University Hospital Wuerzburg / Universitätsklinikum Würzburg Maastricht University Maastricht Catholic University of Leuven = Katholieke Universiteit Leuven (KU Leuven) The Netherlands Heart Institute R.A.d.B. is supported by the Netherlands Heart Foundation (CVON DOSIS, grant 2014-40, CVON SHE-PREDICTS-HF, grant 2017-21, and CVON RED-CVD, grant 2017-11); and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350). J.B. is supported is supported by the Deutsche Forschungsgemeinschaft (DFG), Clinical Research Group 311 (KFO 311) ‘(Pre)terminal heart and lung failure: unloading and repair’ (DFG; TP1, BA 1742/9-1) and ‘MR-Focus’‘ (DFG BA 1742/8-1). J.S. has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (consolidator grant Evicare #725229) and by the Netherlands Heart Foundation (CVON-HUSTCARE). M.M. is a BHF Chair Holder (CH/16/3/32406), with BHF program grant support (RG/16/14/32397), and was awarded a BHF Special Project grant to participate in the ERA-CVD Translational Grant MacroERA. M.M. and T.T. are members of a network funded by the Foundation Leducq. C.G.T. is supported by a Federico II University/Ricerca di Ateneo grant. S.H. has received funding from the European Union Commission's Seventh Framework programme under grant agreement n. 305507 (HOMAGE), n. 602904 (FIBROTARGETS) and FP7-Health-2013-Innovations-1 n. 602156 (HECATOS), CVON2016-Early HFPEF, 2015-10, and CVON SHE-PREDICTS-HF, grant 2017-21. C.M. is supported by the DFG (Ma 2528/7-1, SFB 894, TRR-219) and the Federal Ministry of Education and Science (BMBF; 01EO150, CF.3, RC2). European Project: 305507 European Project: 602904,EC:FP7:HEALTH,FP7-HEALTH-2013-INNOVATION-1,FIBRO-TARGETS(2013) European Project: 602156,EC:FP7:HEALTH,FP7-HEALTH-2013-INNOVATION-1,HECATOS(2013) |
format |
Article in Journal/Newspaper |
author |
de Boer, Rudolf, A de Keulenaer, Gilles Bauersachs, Johann Brutsaert, Dirk Cleland, John, G Diez, Javier Du, Xiao‐jun Ford, Paul Heinzel, Frank, R Lipson, Kenneth, E Mcdonagh, Theresa Lopez-Andres, Natalia Lunde, Ida, G Lyon, Alexander, R Pollesello, Piero Prasad, Sanjay, K Tocchetti, Carlo, G Mayr, Manuel Sluijter, Joost P.G. Thum, Thomas Tschöpe, Carsten Zannad, Faiez Zimmermann, Wolfram‐hubertus Ruschitzka, Frank Filippatos, Gerasimos Lindsey, Merry, L Maack, Christoph Heymans, Stephane |
author_facet |
de Boer, Rudolf, A de Keulenaer, Gilles Bauersachs, Johann Brutsaert, Dirk Cleland, John, G Diez, Javier Du, Xiao‐jun Ford, Paul Heinzel, Frank, R Lipson, Kenneth, E Mcdonagh, Theresa Lopez-Andres, Natalia Lunde, Ida, G Lyon, Alexander, R Pollesello, Piero Prasad, Sanjay, K Tocchetti, Carlo, G Mayr, Manuel Sluijter, Joost P.G. Thum, Thomas Tschöpe, Carsten Zannad, Faiez Zimmermann, Wolfram‐hubertus Ruschitzka, Frank Filippatos, Gerasimos Lindsey, Merry, L Maack, Christoph Heymans, Stephane |
author_sort |
de Boer, Rudolf, A |
title |
Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology |
title_short |
Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology |
title_full |
Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology |
title_fullStr |
Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology |
title_full_unstemmed |
Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology |
title_sort |
towards better definition, quantification and treatment of fibrosis in heart failure. a scientific roadmap by the committee of translational research of the heart failure association (hfa) of the european society of cardiology |
publisher |
HAL CCSD |
publishDate |
2019 |
url |
https://hal.univ-lorraine.fr/hal-03764243 https://hal.univ-lorraine.fr/hal-03764243/document https://hal.univ-lorraine.fr/hal-03764243/file/European%20J%20of%20Heart%20Fail%20-%202019%20-%20de%20Boer%20-%20Towards%20better%20definition%20%20quantification%20and%20treatment%20of%20fibrosis%20in%20heart.pdf https://doi.org/10.1002/ejhf.1406 |
genre |
SCAR |
genre_facet |
SCAR |
op_source |
ISSN: 1388-9842 European Journal of Heart Failure https://hal.univ-lorraine.fr/hal-03764243 European Journal of Heart Failure, 2019, 21 (3), pp.272-285. ⟨10.1002/ejhf.1406⟩ |
op_relation |
info:eu-repo/semantics/altIdentifier/doi/10.1002/ejhf.1406 info:eu-repo/semantics/altIdentifier/pmid/30714667 info:eu-repo/grantAgreement//305507/EU/HOMAGE (Heart Omics in Ageing consortium)/ info:eu-repo/grantAgreement/EC/FP7/602904/EU/Targeting cardiac fibrosis for heart failure treatment/FIBRO-TARGETS info:eu-repo/grantAgreement/EC/FP7/602156/EU/Hepatic and Cardiac Toxicity Systems modelling/HECATOS hal-03764243 https://hal.univ-lorraine.fr/hal-03764243 https://hal.univ-lorraine.fr/hal-03764243/document https://hal.univ-lorraine.fr/hal-03764243/file/European%20J%20of%20Heart%20Fail%20-%202019%20-%20de%20Boer%20-%20Towards%20better%20definition%20%20quantification%20and%20treatment%20of%20fibrosis%20in%20heart.pdf doi:10.1002/ejhf.1406 PUBMED: 30714667 PUBMEDCENTRAL: PMC6607480 |
op_rights |
info:eu-repo/semantics/OpenAccess |
op_doi |
https://doi.org/10.1002/ejhf.1406 |
container_title |
European Journal of Heart Failure |
container_volume |
21 |
container_issue |
3 |
container_start_page |
272 |
op_container_end_page |
285 |
_version_ |
1786199746272034816 |
spelling |
ftccsdartic:oai:HAL:hal-03764243v1 2023-12-24T10:24:41+01:00 Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology de Boer, Rudolf, A de Keulenaer, Gilles Bauersachs, Johann Brutsaert, Dirk Cleland, John, G Diez, Javier Du, Xiao‐jun Ford, Paul Heinzel, Frank, R Lipson, Kenneth, E Mcdonagh, Theresa Lopez-Andres, Natalia Lunde, Ida, G Lyon, Alexander, R Pollesello, Piero Prasad, Sanjay, K Tocchetti, Carlo, G Mayr, Manuel Sluijter, Joost P.G. Thum, Thomas Tschöpe, Carsten Zannad, Faiez Zimmermann, Wolfram‐hubertus Ruschitzka, Frank Filippatos, Gerasimos Lindsey, Merry, L Maack, Christoph Heymans, Stephane University Medical Center Groningen Groningen (UMCG) University of Antwerp (UA) Medizinische Hochschule Hannover = Hannover Medical School (MHH) University of Glasgow Center for Applied Medical Research Plamplona (CIMA) Universidad de Navarra Pamplona (UNAV) Clínica Universidad de Navarra Pamplona Baker Heart and Diabetes Institute (AUSTRALIA) Galecto Biotech Charité Campus Virchow-Klinikum (CVK) Charité - UniversitätsMedizin = Charité - University Hospital Berlin FibroGen Inc. King's College Hospital (KCH) Universidad Pública de Navarra Espagne = Public University of Navarra (UPNA) Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA) Universidad Pública de Navarra Espagne = Public University of Navarra (UPNA)-Universidad de Navarra Pamplona (UNAV)-Clínica Universidad de Navarra Pamplona University of Oslo (UiO) Oslo University Hospital Oslo Royal Brompton Hospital Orion Pharma University of Naples Federico II = Università degli studi di Napoli Federico II King‘s College London University Medical Center Utrecht Institute of Molecular and Translational Therapeutic Strategies (IMTTS) German Center for Cardiovascular Research (DZHK) Berlin Institute of Health (BIH) Centre d'investigation clinique plurithématique Pierre Drouin Nancy (CIC-P) Centre d'investigation clinique Nancy (CIC) Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL) Défaillance Cardiovasculaire Aiguë et Chronique (DCAC) Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL) Cardiovascular and Renal Clinical Trialists Vandoeuvre-les-Nancy (INI-CRCT) Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu Nancy French-Clinical Research Infrastructure Network - F-CRIN Paris (Cardiovascular & Renal Clinical Trialists - CRCT ) University Medical Center Göttingen (UMG) University hospital of Zurich Zurich “Attikon” University Hospital University of Mississippi Medical Center (UMMC) Julius-Maximilians-Universität Würzburg (JMU) University Hospital Wuerzburg / Universitätsklinikum Würzburg Maastricht University Maastricht Catholic University of Leuven = Katholieke Universiteit Leuven (KU Leuven) The Netherlands Heart Institute R.A.d.B. is supported by the Netherlands Heart Foundation (CVON DOSIS, grant 2014-40, CVON SHE-PREDICTS-HF, grant 2017-21, and CVON RED-CVD, grant 2017-11); and the Innovational Research Incentives Scheme program of the Netherlands Organization for Scientific Research (NWO VIDI, grant 917.13.350). J.B. is supported is supported by the Deutsche Forschungsgemeinschaft (DFG), Clinical Research Group 311 (KFO 311) ‘(Pre)terminal heart and lung failure: unloading and repair’ (DFG; TP1, BA 1742/9-1) and ‘MR-Focus’‘ (DFG BA 1742/8-1). J.S. has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (consolidator grant Evicare #725229) and by the Netherlands Heart Foundation (CVON-HUSTCARE). M.M. is a BHF Chair Holder (CH/16/3/32406), with BHF program grant support (RG/16/14/32397), and was awarded a BHF Special Project grant to participate in the ERA-CVD Translational Grant MacroERA. M.M. and T.T. are members of a network funded by the Foundation Leducq. C.G.T. is supported by a Federico II University/Ricerca di Ateneo grant. S.H. has received funding from the European Union Commission's Seventh Framework programme under grant agreement n. 305507 (HOMAGE), n. 602904 (FIBROTARGETS) and FP7-Health-2013-Innovations-1 n. 602156 (HECATOS), CVON2016-Early HFPEF, 2015-10, and CVON SHE-PREDICTS-HF, grant 2017-21. C.M. is supported by the DFG (Ma 2528/7-1, SFB 894, TRR-219) and the Federal Ministry of Education and Science (BMBF; 01EO150, CF.3, RC2). European Project: 305507 European Project: 602904,EC:FP7:HEALTH,FP7-HEALTH-2013-INNOVATION-1,FIBRO-TARGETS(2013) European Project: 602156,EC:FP7:HEALTH,FP7-HEALTH-2013-INNOVATION-1,HECATOS(2013) 2019-02-14 https://hal.univ-lorraine.fr/hal-03764243 https://hal.univ-lorraine.fr/hal-03764243/document https://hal.univ-lorraine.fr/hal-03764243/file/European%20J%20of%20Heart%20Fail%20-%202019%20-%20de%20Boer%20-%20Towards%20better%20definition%20%20quantification%20and%20treatment%20of%20fibrosis%20in%20heart.pdf https://doi.org/10.1002/ejhf.1406 en eng HAL CCSD European Society of Cardiology (Wiley) info:eu-repo/semantics/altIdentifier/doi/10.1002/ejhf.1406 info:eu-repo/semantics/altIdentifier/pmid/30714667 info:eu-repo/grantAgreement//305507/EU/HOMAGE (Heart Omics in Ageing consortium)/ info:eu-repo/grantAgreement/EC/FP7/602904/EU/Targeting cardiac fibrosis for heart failure treatment/FIBRO-TARGETS info:eu-repo/grantAgreement/EC/FP7/602156/EU/Hepatic and Cardiac Toxicity Systems modelling/HECATOS hal-03764243 https://hal.univ-lorraine.fr/hal-03764243 https://hal.univ-lorraine.fr/hal-03764243/document https://hal.univ-lorraine.fr/hal-03764243/file/European%20J%20of%20Heart%20Fail%20-%202019%20-%20de%20Boer%20-%20Towards%20better%20definition%20%20quantification%20and%20treatment%20of%20fibrosis%20in%20heart.pdf doi:10.1002/ejhf.1406 PUBMED: 30714667 PUBMEDCENTRAL: PMC6607480 info:eu-repo/semantics/OpenAccess ISSN: 1388-9842 European Journal of Heart Failure https://hal.univ-lorraine.fr/hal-03764243 European Journal of Heart Failure, 2019, 21 (3), pp.272-285. ⟨10.1002/ejhf.1406⟩ Fibrosis Heart failure Biomarkers Fibroblast Matrix Prognosis Imaging [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system info:eu-repo/semantics/article Journal articles 2019 ftccsdartic https://doi.org/10.1002/ejhf.1406 2023-11-26T00:03:03Z International audience Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins - resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research. Article in Journal/Newspaper SCAR Archive ouverte HAL (Hyper Article en Ligne, CCSD - Centre pour la Communication Scientifique Directe) European Journal of Heart Failure 21 3 272 285 |